These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 33245350)

  • 1. Hepatitis C Virus Treatment: Simplifying the Simple and Optimizing the Difficult.
    Falade-Nwulia O; Sulkowski MS
    J Infect Dis; 2020 Nov; 222(Suppl 9):S745-S757. PubMed ID: 33245350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Hepatitis C/HIV Coinfection in the Era of Highly Effective Hepatitis C Virus Direct-Acting Antiviral Therapy.
    Wyles DL; Sulkowski MS; Dieterich D
    Clin Infect Dis; 2016 Jul; 63 Suppl 1(Suppl 1):S3-S11. PubMed ID: 27363438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIV.
    MacBrayne CE; Kiser JJ
    Clin Infect Dis; 2016 Jul; 63 Suppl 1(Suppl 1):S12-23. PubMed ID: 27363437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver Transplant From Increased-Risk Donors in the Era of Direct-Acting Antivirals for Hepatitis C.
    Shaikh OS; Rogal S; Malik A; Sharma V; Cacciarelli T
    Exp Clin Transplant; 2020 Oct; 18(5):605-611. PubMed ID: 31324136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study.
    Chen Q; Ayer T; Bethea E; Kanwal F; Wang X; Roberts M; Zhuo Y; Fagiuoli S; Petersen J; Chhatwal J
    BMJ Open; 2019 Jun; 9(6):e026726. PubMed ID: 31189677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world treatment for chronic hepatitis C infection in Germany: Analyses from drug prescription data, 2010-2015.
    Zimmermann R; Kollan C; Ingiliz P; Mauss S; Schmidt D; Bremer V
    J Hepatol; 2017 Jul; 67(1):15-22. PubMed ID: 28189752
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A population approach to disease management: hepatitis C direct-acting antiviral use in a large health care system.
    Belperio PS; Backus LI; Ross D; Neuhauser MM; Mole LA
    J Manag Care Spec Pharm; 2014 Jun; 20(6):533-40. PubMed ID: 24856591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India.
    Aggarwal R; Chen Q; Goel A; Seguy N; Pendse R; Ayer T; Chhatwal J
    PLoS One; 2017; 12(5):e0176503. PubMed ID: 28520728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Revolutionizing hepatitis C treatment: next-gen direct-acting antivirals.
    Dobrowolska K; Brzdęk M; Rzymski P; Flisiak R; Pawłowska M; Janczura J; Brzdęk K; Zarębska-Michaluk D
    Expert Opin Pharmacother; 2024 May; 25(7):833-852. PubMed ID: 38768013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simplified treatment of hepatitis C: another strategy to overcome the barriers to its elimination.
    Ridruejo E; Mendizabal M; Silva MO
    Medicina (B Aires); 2021; 81(2):252-256. PubMed ID: 33906144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in practice and perception of hepatitis C and liver transplantation: Results of a national survey.
    Shaffer AA; Thomas AG; Bowring MG; Van Pilsum Rasmussen SE; Cash A; Kucirka LM; Alqahtani SA; Gurakar A; Sulkowski MS; Cameron AM; Segev DL; Durand CM
    Transpl Infect Dis; 2018 Dec; 20(6):e12982. PubMed ID: 30144258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Hepatitis C Infection in children in the era of Direct-acting Antiviral Agents.
    Karnsakul W; Schwarz KB
    J Viral Hepat; 2019 Sep; 26(9):1034-1039. PubMed ID: 30980688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A new challenge in clinical practice: resistance to directly acting antivirals in hepatitis C treatment].
    Chen ZW; Hu P; Ren H
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):165-9. PubMed ID: 27095757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The safety of daclatasvir for the treatment of hepatitis C.
    Jafri SM; Gordon SC
    Expert Opin Drug Saf; 2015; 14(11):1787-97. PubMed ID: 26571362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What do clinicians need to watch for with direct-acting antiviral therapy?
    Aghemo A; Piroth L; Bhagani S
    J Int AIDS Soc; 2018 Apr; 21 Suppl 2(Suppl Suppl 2):e25076. PubMed ID: 29633552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient and healthcare provider experiences of hepatitis C treatment with direct-acting antivirals in Rwanda: a qualitative exploration of barriers and facilitators.
    Serumondo J; Penkunas MJ; Niyikora J; Ngwije A; Kiromera A; Musabeyezu E; Umutesi J; Umuraza S; Musengimana G; Nsanzimana S
    BMC Public Health; 2020 Jun; 20(1):946. PubMed ID: 32546216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapeutic update in hepatitis C].
    Devesa MJ; Cuenca F; Izquierdo S; Sánchez-Pobre P; Ladero JM; López-Alonso G; Díaz-Rubio M; Rey E
    Rev Esp Quimioter; 2015 Sep; 28 Suppl 1():48-51. PubMed ID: 26365735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New Therapies for Hepatitis C Virus.
    Polenakovik H
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(2):119-32. PubMed ID: 27442378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accessing hepatitis C direct acting antivirals among people living with hepatitis C: a qualitative study.
    Antoniou T; Pritlove C; Shearer D; Tadrous M; Shah H; Gomes T
    Int J Equity Health; 2023 Jun; 22(1):112. PubMed ID: 37280588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b.
    Kanda T; Nirei K; Matsumoto N; Higuchi T; Nakamura H; Yamagami H; Matsuoka S; Moriyama M
    World J Gastroenterol; 2017 Dec; 23(46):8120-8127. PubMed ID: 29290649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.